AZN - Astrazeneca PLC Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 DGAZ (0%) ROKU (0%) AAPL (%) UGAZ (0%) AAOI (0%) SPY (0%) SNAP (0%) SBUX (0%) RVLV (0%) PINS (0%) NEWR (0%) LYFT (0%) KOPN (0%) KO (0%) KIM (0%) JNPR (0%) FB (0%) ETSY (%) DIS (%) DHI (0%) CSIQ (0%) CSCO (0%) BZUN (0%) BIDU (0%) ALB (0%)

AZN - Astrazeneca PLC

$47.08 0[0%]

15 mins delayed data

People also watch : LLY | BIIB | JNJ | SNY | BMY | PFE

+Watchlist

4 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$47.08	Open
Volume	4K	Market Cap	124.001B
Yield	0.029%	Last Dividend	$1.37

Day

52 Week

Aravive and AstraZeneca Announce Initiat...	11/12/19
Aravive, Inc. (ARAV) and AstraZeneca (AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL inhibitor, i...

Pfizer-Merck KGaA's Bavencio Fails i...	11/11/19
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patie...

AstraZeneca succeeds in treating lupus i...	11/11/19
AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late...

10 Stocks Poised for 'Blockbuster...	11/10/19
These stocks are expected to new release products or services in the next year with massive sales potential, per analysis by Bloomberg Intelligence.

Don't Sell AstraZeneca PLC (LON:AZN)...	11/10/19
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...

Bulls And Bears Of The Week: Roku, Tesla...	11/09/19
Benzinga has examined the prospects for many investor favorite stocks over the past week. Benzinga continues to examine the prospects for many of the...

UPDATE 1-Safety data on AstraZeneca anae...	11/08/19
AstraZeneca said that safety data on roxadustat underpinned the British drugmaker's hopes for the anaemia drug to become a standard treatment for pati...

Roxadustat Phase III Program Pooled Anal...	11/08/19
In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo

New Data From the Phase III DAPA-HF Tria...	11/08/19
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® for the treatment of heart f...

Pharma Stock Roundup: AGN, NVO Q3 Earnin...	11/08/19
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-a...

Premarket London: BA Parent Cuts Growth ...	11/07/19
Investing.com -- Here is a roundup of regulatory releases from the London Stock Exchange on Friday, 8th November.

ANALYST RATINGS

0 analyst ratings (Last 6 months)

0.00 %

Strong Buy + Buy

Price Target (PT)

EARNINGS

Date	2019-10-24 (BMO)	Est. (EPS/Rev.)	$0.45/ 6.18B
Actual (EPS/Rev.)	$0.99/ $6.41 B	EPS (TTM)	0.8

TRADERS TRACKING $AZN

Service Name	Trader	% Success
Alpha Swing Trades	Jonathan	69.00 %	Follow
LavaPit	Steve Pitkin	58.00 %	Follow
Best Trading Ideas	Best Trading Ideas	52.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.